信函：维多珠单抗用于自身免疫性肝病相关的炎症性肠病——作者回复 - Suppr

Suppr

超能文献

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.

作者信息

Christensen B, Gibson P R, Rubin D T

机构信息

Alfred Hospital and Monash University, Melbourne, Australia.

Royal Melbourne Hospital, Melbourne, Australia.

出版信息

Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.

DOI:10.1111/apt.14638

PMID:29676007

Abstract

摘要

相似文献

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.

Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.

Aliment Pharmacol Ther. 2018 May;47(10):1422-1423. doi: 10.1111/apt.14603.

Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.

Aliment Pharmacol Ther. 2017 Jan;45(2):376-378. doi: 10.1111/apt.13861.

Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series.

Inflamm Bowel Dis. 2016 Oct;22(10):E39-40. doi: 10.1097/MIB.0000000000000906.

Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.

Aliment Pharmacol Ther. 2018 Sep;48(5):578-579. doi: 10.1111/apt.14907.

All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):51-53. doi: 10.1016/j.cgh.2019.07.020. Epub 2019 Jul 16.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.

Aliment Pharmacol Ther. 2018 Aug;48(3):388-389. doi: 10.1111/apt.14855.

Vedolizumab in IBD/PSC: A Case for Careful Vigilance?

J Crohns Colitis. 2019 Sep 27;13(10):1237-1238. doi: 10.1093/ecco-jcc/jjz102.

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.

Aliment Pharmacol Ther. 2023 Mar;57(6):743-744. doi: 10.1111/apt.17407.

Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.

Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570.

引用本文的文献

Vedolizumab in Inflammatory Bowel Disease: West versus East.

Inflamm Intest Dis. 2021 Feb;6(1):1-17. doi: 10.1159/000512805. Epub 2021 Jan 27.

An update on treatment options for primary sclerosing cholangitis.

Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):115-124.

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Curr Hepatol Rep. 2019;18(1):115-126. doi: 10.1007/s11901-019-00456-2. Epub 2019 Mar 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.

作者信息

Christensen B, Gibson P R, Rubin D T

机构信息

Alfred Hospital and Monash University, Melbourne, Australia.

Royal Melbourne Hospital, Melbourne, Australia.

出版信息

Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.

DOI:10.1111/apt.14638

PMID:29676007

Abstract

摘要

相似文献

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.

Aliment Pharmacol Ther. 2018 May;47(10):1423-1424. doi: 10.1111/apt.14638.

Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.

Aliment Pharmacol Ther. 2018 May;47(10):1422-1423. doi: 10.1111/apt.14603.

Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.

Aliment Pharmacol Ther. 2017 Jan;45(2):376-378. doi: 10.1111/apt.13861.

Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series.

Inflamm Bowel Dis. 2016 Oct;22(10):E39-40. doi: 10.1097/MIB.0000000000000906.

Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.

Aliment Pharmacol Ther. 2018 Sep;48(5):578-579. doi: 10.1111/apt.14907.

All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):51-53. doi: 10.1016/j.cgh.2019.07.020. Epub 2019 Jul 16.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.

Aliment Pharmacol Ther. 2018 Aug;48(3):388-389. doi: 10.1111/apt.14855.

Vedolizumab in IBD/PSC: A Case for Careful Vigilance?

J Crohns Colitis. 2019 Sep 27;13(10):1237-1238. doi: 10.1093/ecco-jcc/jjz102.

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.

Aliment Pharmacol Ther. 2023 Mar;57(6):743-744. doi: 10.1111/apt.17407.

Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.

Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570.

引用本文的文献

Vedolizumab in Inflammatory Bowel Disease: West versus East.

Inflamm Intest Dis. 2021 Feb;6(1):1-17. doi: 10.1159/000512805. Epub 2021 Jan 27.

An update on treatment options for primary sclerosing cholangitis.

Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):115-124.

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Curr Hepatol Rep. 2019;18(1):115-126. doi: 10.1007/s11901-019-00456-2. Epub 2019 Mar 7.